TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04111185

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receive Blood Volume Analysis Guided Treatment
Description: The health care team will be given the results of the blood volume analysis along with guidance on how to provide treatment based on the analysis
Study: NCT01502410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT03016624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OCT guided PCI
Description: oct guided

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography guided PCI
Description: angio guided
Study: NCT01534299

Intervention type: DEVICE
Intervention: Medtronic Renal Denervation System
Description: The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
Study: NCT04115878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine and oxybutynin (ato-oxy)
Description: Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine and oxybutynin (ato-oxy)
Description: Low dose ato-oxy will include 0.5 mg/kg/day of atomoxetine (max 40 mg) in combination with 5 mg oxybutynin High dose ato-oxy will include 1.2 mg/kg/day atomoxetine (max 80 mg) and 5 mg oxybutynin
Study: NCT02031991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06439535
Description: Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
Study: NCT04653090

Intervention type: DIAGNOSTIC_TEST
Intervention: Xray
Description: Hip AP Xray

Intervention type: DIAGNOSTIC_TEST
Intervention: Xray
Description: Hip AP Xray
Study: NCT02782975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aducanumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aducanumab
Study: NCT00616395

Intervention type: DEVICE
Intervention: No intervention
Study: NCT01699282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VKA (antivitamin K) education
Description: Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional hospital education
Description: Group thorough VKA education V.S. control group (conventional hospital education)
Study: NCT04186520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8/12-Day Production of Car-T Cells
Description: A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8/12-Day Production of Car-T Cells
Description: A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8/12-Day Production of Car-T Cells
Description: A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8/12-Day Production of Car-T Cells
Description: A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 8/12-Day Production of Cryopreserved Car-T Cells
Description: A fixed cryopreserved dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 12-Day Production of Car-T Cells
Description: A fixed dose of 2.5 x 10\^6 CAR-20/19-T cells/kg expanded with IL-7/IL-15.
Study: NCT00754260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caffeine reduction
Description: patients are randomized to receive caffeine reduction counseling versus no caffeine reduction counseling
Study: NCT01116011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: Capsule, Oral, BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule, Oral, BID
Study: NCT03241251

Intervention type: OTHER
Intervention: questionnaire
Description: Questionnaire of psychosocial risk factors
Study: NCT05787457

Intervention type: OTHER
Intervention: Clinical examination

Intervention type: OTHER
Intervention: Clinical examination

Intervention type: OTHER
Intervention: Clinical examination

Intervention type: OTHER
Intervention: Blood testing

Intervention type: OTHER
Intervention: Blood testing

Intervention type: OTHER
Intervention: Blood testing

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: MRI
Study: NCT00603889

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Na-ASP-2 Skin Test Reagent
Description: Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
Study: NCT03234686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone 600mg delayed release tablets
Description: The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
Study: NCT02235480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Tazarotene Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00160251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boceprevir (BOC)
Description: 100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
Study: NCT03234374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Marcaine 0.25% infiltration
Description: Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
Study: NCT00160251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
Study: NCT03204032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Tegafur 40-60mg po bid(d1-d14);
Study: NCT00160251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir (BOC)
Description: 100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron (PEG)
Description: 1.5 mcg/kg weekly subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PegIntron (PEG)
Description: 1.5 mcg/kg weekly subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (PEG)
Description: 1.5 mcg/kg weekly subcutaneously
Study: NCT03204032

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur
Description: Tegafur 40-60mg po bid(d1-d14);

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200mg po qd(d10-d14)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: 200mg po qd(d10-d14)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)
Study: NCT00354484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous Sulfate tablets
Description: 325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
Study: NCT04161313

Intervention type: OTHER
Intervention: Measurement of functional capacity
Description: Functional capacity of participants will be measured with six-minute walk test.

Intervention type: OTHER
Intervention: Measurement of functional capacity
Description: Functional capacity of participants will be measured with six-minute walk test.

Intervention type: OTHER
Intervention: Measurement of functional capacity
Description: Functional capacity of participants will be measured with six-minute walk test.

Intervention type: OTHER
Intervention: pulmonary function test
Description: It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75

Intervention type: OTHER
Intervention: pulmonary function test
Description: It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75

Intervention type: OTHER
Intervention: pulmonary function test
Description: It will be measured using basic spirometry and presented lung volume parameters such as FEV1,FVC,FEV1/FVC,PEF, FEF25-75

Intervention type: OTHER
Intervention: Functional capacity
Description: Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test

Intervention type: OTHER
Intervention: Functional capacity
Description: Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test

Intervention type: OTHER
Intervention: Functional capacity
Description: Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test

Intervention type: OTHER
Intervention: Peripheral muscle strength
Description: Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.

Intervention type: OTHER
Intervention: Peripheral muscle strength
Description: Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.

Intervention type: OTHER
Intervention: Peripheral muscle strength
Description: Isometric M. Quadriceps strength will be measured using electronic hand held dynamometer in sitting position.

Intervention type: OTHER
Intervention: Respiratory muscle strength
Description: Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.

Intervention type: OTHER
Intervention: Respiratory muscle strength
Description: Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.

Intervention type: OTHER
Intervention: Respiratory muscle strength
Description: Inspiratory and expiratory muscle strength has been assessed by maximal inspiratory and expiratory mouth pressures.
Study: NCT04290767

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy)
Description: Enhanced-contrast brain ultrasound with intravenously sulphur hexafluoride microbubbles SONOVUE (BRACCO, Milan, Italy) injection and using the time-intensity curve profile to evaluate brain microcirculation.
Study: NCT04396106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT-527
Description: One 550 mg tablet of AT-527 administered every \~12 hours (twice a day) for a total of 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo tablet administered every \~12 hours (twice a day) for a total of 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AT-527
Description: Two 550 mg tablets of AT-527 administered every \~12 hours (twice a day) for a total of 5 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets administered every \~12 hours (twice a day) for a total of 5 days
Study: NCT02397772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albendazole
Description: Single dose of albendazole (400 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole
Description: Single dose of albendazole (400 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albendazole
Description: Single dose of albendazole (400 mg)
Study: NCT01723124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Molecular Breast Imaging
Description: Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
Study: NCT01081951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: Tablets Oral BID
Study: NCT01502410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study: NCT00998452

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MOVE*VETS
Description: Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
Study: NCT03021655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adventure-based intervention group
Description: One-day adventure-based training will be assigned to subjects and the activities include wall climbing, rope course and health talk on mood, pressure management and smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WhatsApp intervention group
Description: A WhatsApp group will be opened for the subjects and we will send messages about mood and pressure management to them and encourage them to quit smoking. The subjects can share their unhappy things in the group.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Description: Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12-, 24-month and smoking cessation counselling will be delivered to the subjects.
Study: NCT02370316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Interpersonal Therapy (MIT-SA)
Description: MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
Study: NCT04648202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS120
Description: Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.
Study: NCT02370316

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Structured Treatment
Description: structured case management and symptom-targeted medication
Study: NCT00943098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac HPBCD s.c. 75mg/ml
Description: 1 single injection at day of dental surgical extraction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voltarol 75mg/3ml i.m.
Description: 1 single injection at day of dental surgical extraction
Study: NCT02066948

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wt loss
Description: subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: wt loss
Description: subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
Study: NCT02547246

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS session
Description: One session of rTMS at a frequency of 10 Hz during 20 minutes

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: rTMS Placebo (SHAM)
Description: One session of placebo (SHAM) rTMS during 20 minutes
Study: NCT01877525

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
Study: NCT00160251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (PEG)
Description: 1.5 mcg/kg weekly subcutaneously
Study: NCT01081951

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175mg/m2 iv for up to 6 cycles (18 weeks)
Study: NCT00160251

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (PEG)
Description: 1.5 mcg/kg weekly subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (PEG)
Description: 1.5 mcg/kg weekly subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (PEG)
Description: 1.5 mcg/kg weekly subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (PEG)
Description: 1.5 mcg/kg weekly subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIntron (PEG)
Description: 1.5 mcg/kg weekly subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight \[weight-based dosing {WBD}\])

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight \[weight-based dosing {WBD}\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight \[weight-based dosing {WBD}\])

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight \[weight-based dosing {WBD}\])
Study: NCT02573298

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ice
Description: local ice application for 30 minutes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cold gas
Description: local cold gas application for 2 minutes
Study: NCT04069494

Intervention type: OTHER
Intervention: questionnaires
Description: Two questionnaires in patients and another two questionnaires in carer.

Intervention type: OTHER
Intervention: questionnaires
Description: Two questionnaires in patients and another two questionnaires in carer.
Study: NCT01308671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling and psychosocial support
Description: Blank group will receive the same counseling and psychosocial support as varenicline group
Study: NCT01081951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: carboplatin
Description: AUC4 iv for up to 6 cycles (18 weeks)
Study: NCT03733106

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: digital breast tomosynthesis
Description: pseudo three dimension mammography

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: standard two dimension digital mammogram
Description: standard two dimension mammogram
Study: NCT03261037

Intervention type: OTHER
Group type: OTHER
Intervention: Spirometry
Description: Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.

Intervention type: OTHER
Group type: OTHER
Intervention: Accelerometry
Description: Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.

Intervention type: OTHER
Group type: OTHER
Intervention: 6MWT
Description: The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.